JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES) ›› 2014, Vol. 52 ›› Issue (9): 77-80.doi: 10.6040/j.issn.1671-7554.0.2014.400

Previous Articles     Next Articles

Research on the relationship between plasma D-dimer level and prognosis of breast cancer

LI Ling1, WANG Lili2, WANG Shengjiang2, YU Chao2, LIU Yanpeng2, XU Chengwei2   

  1. 1. Department of Surgery, Shandong Provincial Tumor Hospital, Jinan 250117, Shandong, China;
    2. Department of Laboratory Medicine, Second Hospital of Shandong University, Jinan 250033, Shandong, China
  • Received:2014-06-16 Revised:2014-09-04 Online:2014-09-10 Published:2014-09-10
  • Contact: 徐成伟。E-mail:xuchengwei-jyk@163.com E-mail:xuchengwei-jyk@163.com

PDF (PC)

358

Abstract: Objective To analyze the changes of plasma D-dimer level in breast cancer patients, and to investigate the relationship between the level of D-dimer and prognosis of breast cancer. Methods A total of 92 cases of primary breast cancer and 85 healthy controls were enrolled. The level of D-dimer was measured with latex-enhanced immunoassay, and ER, PR, HER2, Ki-67 and P53 levels were detected with immunohistochemical methods. During the follow-up of 8 months, the plasma D-dimer levels in breast cancer patients were analyzed. Results The level of D-dimer in breast cancer patients was significantly higher compared to that of the healthy controls (P<0.01); the level of D-dimer in survivors during follow-up was significantly lower than that in those who died (P<0.05); the level of plasma D-dimer in breast cancer patients with different expressions of ER, PR, HER2, Ki-67 and P53 showed no significant difference (P>0.05). Conclusion D-dimer can act as a predictor of breast cancer prognosis, while it has nothing to do with other immunohistochemical indexes.

Key words: Breast cancer, D-dimer, Prognosis, Immunohistochemistry

CLC Number: 

  • R737.9
[1] Falanga A, Marchetti M, Vignoli A. Coagulation and cancer: biological and clinical aspects[J]. Journal of Thrombosis and Haemostasis, 2013, 11(2): 223-233.
[2] Zacharski L R, Ornstein D L. Venous thromboembolism and cancer[J]. N Eng J Med, 2000, 343(5): 1338-47.
[3] Dirix L Y, Salgado R, Weytjens R, et al. Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer[J]. Br J Cancer, 2002, 86(11): 389-395.
[4] Benoy I H, Salgado R, Elst H, et al. Relative microve-ssel area of the primary tumour, and not lymph node sta-tus, predicts the presence of bone marrow micrometasta-ses detected by reverse transcriptase polymerase chain re-action in patients with clinically non-metastatic breast cancer[J]. Breast Cancer Res, 2005, 7(2): 210-219.
[5] Kono T, Ohtsuki T, Hosomi N, et al. Clinical character-istics of ischemic stroke in elderly patients with cancer[J]. Nihon Ronen Igakai Zasshi, 2011, 48(1): 57-62.
[6] 王丽丽, 徐成伟. 恶性肿瘤血栓形成机制研究进展[J]. 血栓与止血学杂志, 2013, 19(5): 237-240. WANG Lili, XU Chengwei. Advances of Study on Thrombosis in Malignant Tumor[J]. Chinese Journal of Thrombosis and Haemostasis, 2013, 19 (5): 237-240.
[7] 王胜江, 徐成伟. 血浆中凝血酶激活的纤溶抑制物(TAFI)水平与慢性肝损伤相关性研究[J]. 山东大学学报: 医学版, 2012, 50(4): 83-86. WANG Shengjiang, XU Chengwei. Circulating levels of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) in patients with chronic liver disease[J]. Journal of Shan-dong University: Health Sciences, 2012, 50(4): 83-86.
[8] Batschauer A P, Figueiredo C P, Bueno E C, et al. D-di-mer as a possible prognostic marker of operable hormone receptor-negative breast cancer[J]. Ann Oncol, 2010, 21(6): 1267-1272.
[9] Ay C I, Dunkler D, Pirker R, et al. High D-dimer levels are associated with poor prognosis in cancer patients[J]. Haematologica, 2012, 97(8): 1158-1164.
[10] Carey L A, Dees E C, Sawyer L, et al. The triple nega-tive paradox: primary tumor chemosensitivity of breast cancer sub-types[J]. Clin Cancer Res, 2007,13 (8): 2329-2334.
[11] Dent R, Trudeau M, Pritchard K I, et al. Triple-nega-tive breast cancer: clinical features and patterns of recur-rence[J].Clin Cancer Res, 2007, 13(15): 4449-4434.
[12] Kausch I, Lingnau A, Endl E et al. Antisense treatment against Ki-67 mRNA inhibits proliferation and tumor growth in vitro and in vivo[J]. Int J Cancer, 2003, 105(12): 710-716.
[13] Rosa F E, Cladeira J R, Felipes J, et al. Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic fac-tors and proliferative marker Ki-67 in breast cancers[J]. Hum Pathol, 2008, 39(5): 720-730.
[14] Versteeg H H, Schaffner F, Kerver M, et al. Inhibition of tissue factor signaling suppresses tumor growth[J]. Blood, 2008, 111(1): 190-199.
[15] Warnberg F, Nordgren H, Bergkvist L, et al. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness[J]. Br J Cancer, 2001, 85(6): 869-874.
[16] Choi H K, Roh S H, Kim H G, et al. Enhanced expression of aromatase in p53-inactivated mammary epithelial cells[J]. Endocr Relat Cancer, 2008, 15(1): 139-147.
[17] Dent R, Trudeau M, Pritchard K I, et al. Prognostic markers in Triple-negative breast cancer[J]. Cancer, 2007, 109(1): 25-32.
[1] GU Chunqing, GUO Ruisi, ZHOU Qinqin, LIU Henghui, BA Wanyu, SUN Shiling, WANG Bing, ZHENG Yuling, WU Suhui. Mechanism of Suanzaoren-Yuanzhi drug pair in the treatment of breast cancer related insomnia based on network pharmacology and animal experiments [J]. Journal of Shandong University (Health Sciences), 2026, 64(1): 99-108.
[2] LI Ziqi, WEI Yanruoxue, LIU Xiaohan, LIU Chuncheng, ZHAO Ran, LIU Yukun. The functional role and clinical significance of lncRNA HEATR3-AS1 in colorectal cancer tumorigenesis and progression [J]. Journal of Shandong University (Health Sciences), 2025, 63(9): 108-115.
[3] LIU Baoguo, SONG Xiang, ZHAO Xiaowen, MAO Yali. Application value of serum STAT5B and NKAIN1 mRNA detection in breast cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(7): 68-74.
[4] WANG Lei, CHANG Xiao, WANG Zimeng, LI Jiaojiao, CUI Shujun, YANG Fei, ZHU Yuexiang. Predictive value of intratumoral and peritumoral DCE-MRI imaging histology for progression-free survival in patients with cervical cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 45-54.
[5] WANG Xuemei, YANG Hao, SONG Yang, CHENG Shichao, ZHANG Tingting, WANG Yanchun. Causal association of antidiabetic drugs with female malignant tumours: a two-sample Mendelian randomisation study [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 67-77.
[6] JIA Ruoxi, LYU Li, LIU Hanyun, WU Yinping, LI Fengcai, ZHAO Zehua, WANG Kai, FAN Yuchen. Diagnostic value of blood cell count-related biomarkers in predicting 28-day mortality in acute-on-chronic hepatitis b liver failure [J]. Journal of Shandong University (Health Sciences), 2025, 63(6): 89-99.
[7] DU Xue, LI Chunxia, LIU Yunxia, ZHANG Tao. Dynamic prediction model for the colorectal cancer patients prognosis based on MFPC-Cox [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 101-110.
[8] YANG Weifang, XU Hong, LIU Yuantao, ZHAO Huichen. Mechanism of thyroid-stimulating immunoglobulin in Graves disease recurrence and clinical significance [J]. Journal of Shandong University (Health Sciences), 2025, 63(4): 116-121.
[9] LIU Wenzhao, ZHANG Yuan, MA Xiangping, WEI Fengtao, BU Peili. Correlation between the pre-endothelial activation and stress index and the mortality risk of patients with heart failure [J]. Journal of Shandong University (Health Sciences), 2025, 63(11): 27-35.
[10] CHEN Wenliang, WANG Huanhuan, HAO Jinjin, GONG Rui, ZHAO Qiang, ZHANG Fei, GAO Lei, DONG Jingxun. The role of lncRNA PVT1 in prognostic assessment and malignant progression of gastric cancer: a study based on nomogram model and functional cellular experiments [J]. Journal of Shandong University (Health Sciences), 2025, 63(10): 61-71.
[11] YU Zhigang, ZHENG Chao. Current status, challenges and innovative approaches of multidisciplinary treatment for breast cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 1-9.
[12] . Shandong Province expert consensus on multidisciplinary treatment of breast cancer(2024 edition) [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 10-16.
[13] CHENG Yueqi, WANG Fei, YU Lixiang, ZHENG Chao, YU Zhigang. Progress in the study of trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 17-24.
[14] WANG Min, LI Xiping, TAN Jun, QIU Mei, HOU Zeyu, TIAN Ying, LUO Hongying, FAN Chaowen, QI Ling, YU Qi, XIE Wei. Lentivirus vector-mediated Gag-Caspase-8 induces apoptosis and S-phase arrest in triple-negative breast cancer primary cells [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 25-34.
[15] ZHANG Jie, ZHANG Fangfang, WANG Jingnan, LI Zeyu, SONG Ying, LI Na. Expression of circ_0000144 in breast cancer and its effect on the proliferation, migration and invasion ability of breast cancer cells [J]. Journal of Shandong University (Health Sciences), 2025, 63(1): 35-42.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd